Abstract:Two series of new pyridyl-bearing fused bicyclic analogues designed to target the dual-tolerant regions of the non-nucleoside reverse transcriptase inhibitor (NNRTI)-binding pocket were synthesized and evaluated for their anti-HIV activities. Several compounds, such as 6, 14, 15, 21, 30, and 33, were found to be potent inhibitors against the wild-type (WT) HIV-1 strain or multiple NNRTI-resistant strains at low nanomolar levels. Detailed structure–activity relationships were obtained by utilizing the variation of moieties within the corresponding pharmacophores. In vitro metabolic stability profiles and some drug-like properties of selected compounds were assessed, furnishing the preliminary structure–metabolic stability relationships. Furthermore, molecular modeling studies elucidated the binding modes of compounds 6, 15, 21, and 30 in the binding pocket of WT, E138K, K103N, or Y181C HIV-1 RTs. These promising compounds can be used as lead compounds and warrant further structural optimization to yield more active HIV-1 inhibitors.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00987.Molecular formula strings (CSV)In vitro anti-HIV assays in MT-4 cells; WT HIV-1 RT inhibition assays; metabolic stability assays in human liver microsomes; molecular modeling; predicted miLogP and MolLogP values of target compounds and controls; mean distance and standard deviation values for selected ligand–protein contacts in simulated systems; regression analysis of miLogP values and MolLogP values; rmsd profiles for the protein backbone, NNRTI-binding site, and simulated inhibitors for the RT-inhibitor complexes; time-dependent distance distribution for d1–d4 for RT-inhibitor complexes; representation of the molecular interaction potential for the interaction of compounds 6, 15, 21, and 30 with a positively and a negatively charged atom; and 1H NMR, 13C NMR, and ESI-MS spectra for the target compounds (PDF).This article has not yet been cited by other publications.

"Pseudosubstrate Envelope"/Free Energy Perturbation-Guided Design and Mechanistic Investigations of Benzothiazole HIV Capsid Modulators with High Ligand Efficiency

Discovery of 5-Alkyl-2-pyrazol-oxazolidin-4-one Derivatives As Novel Hepatitis B Virus Capsid Assembly Modulators

Discovery and Mechanistic Investigation of Piperazinone Phenylalanine Derivatives with Terminal Indole or Benzene Ring as Novel HIV-1 Capsid Modulators

Quinazolinone-based subchemotypes for targeting HIV-1 capsid protein: design and synthesis

Discovery, Crystallographic Studies, and Mechanistic Investigations of Novel Phenylalanine Derivatives Bearing a Quinazolin-4-one Scaffold as Potent HIV Capsid Modulators

Design and Synthesis of New GS-6207 Subtypes for Targeting HIV-1 Capsid Protein

Design, synthesis, and antiviral activity of phenylalanine derivatives as HIV-1 capsid inhibitors

Screening Novel HIV-1 Protease Inhibitors Based on the Substrate Envelope Hypothesis

Discovery of low‐molecular‐weight phenylalanine derivatives as novel HIV capsid modulators with improved antiretroviral activity and metabolic stability

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.

Design and Evaluation of Novel HIV-1 Protease Inhibitors Containing Phenols or Polyphenols as P2 Ligands with High Activity against DRV-Resistant HIV-1 Variants

Structure-based design, synthesis, and biological characterization of indolylarylsulfone derivatives as novel human immunodeficiency virus type 1 inhibitors with potent antiviral activities and favorable drug-like profiles

Synthesis and Biological Evaluation of Pyridinone Analogues As Novel Potent HIV-1 NNRTIs.

Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies

Structure-based design and optimization lead to the identification of novel dihydrothiopyrano[3,2- d]pyrimidine derivatives as potent HIV-1 inhibitors against drug-resistant variants

2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies

Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-[1,3,5]triazin-2-ylamino)-5-methoxy-2-methylphenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives

Structure-guided optimization of small molecules inhibiting human immunodeficiency virus 1 Tat association with the human coactivator p300/CREB binding protein-associated factor.

Structure-guided Design of Novel Biphenyl-Quinazoline Derivatives As Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Improved Anti-Resistance, Selectivity, and Solubility

Structure based design and evaluation of benzoheterocycle derivatives as potential dual HIV-1 protease and reverse transcriptase inhibitors

Multitargeted Drug Design Strategy for Discovery of Short-Peptide-based HIV-1 Entry Inhibitors with High Potency